Jasper Therapeutics (JSPR) Income towards Parent Company (2020 - 2025)

Jasper Therapeutics' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$16.0 million for Q4 2025.

• In Q4 2025, Income towards Parent Company rose 35.08% year-over-year to -$16.0 million; the TTM figure through Dec 2025 stood at -$85.1 million (down 11.17% YoY), while the FY2025 annual figure was -$84.0 million, down 7.94% from the prior year.
• Income towards Parent Company for Q4 2025 stood at -$16.0 million, up from -$18.9 million in the prior quarter.
• The five-year high for Income towards Parent Company was $11.9 million in Q3 2022, with the low at -$28.9 million in Q2 2025.
• The 5-year median for Income towards Parent Company is -$15.5 million (2024), against an average of -$13.5 million.
• The sharpest annual moves came in 2021 and 2022: Income towards Parent Company jumped 1663.89% in 2021, then tumbled 422.68% in 2022.
• Jasper Therapeutics' Income towards Parent Company stood at -$11.9 million in 2021, then decreased by 19.41% to -$14.2 million in 2022, then slipped by 17.77% to -$16.8 million in 2023, then slumped by 46.88% to -$24.6 million in 2024, then surged by 35.08% to -$16.0 million in 2025.
• Business Quant data shows JSPR's Income towards Parent Company at -$16.0 million in Q4 2025, -$18.9 million in Q3 2025, and -$28.9 million in Q2 2025.